Wang Xiaodong 4

What Happened
Wang Xiaodong, a director and chair of the Scientific Advisory Board at BeOne Medicines (ONC), received two grants on June 11, 2026: 99,892 shares and 193,492 shares reported as awards (code A), totaling 293,384 restricted share units (RSUs). Both grants show a $0 transaction price because these are equity awards (not open-market purchases or sales). These awards are reported as including derivative securities (RSUs representing underlying ordinary shares).

Key Details

• Transaction date: 2026-06-11; Form 4 filed: 2026-06-15 (filed within the 2-business-day window).
• Grants: 99,892 shares (award) and 193,492 shares (award/derivative) — total 293,384 RSUs; reported price $0.
• Vesting: Footnotes indicate multi-year vesting over four years — 25% on the first anniversary of June 11, 2026, with remaining shares vesting either annually or in 36 monthly installments thereafter, subject to continued service; unvested securities may accelerate on certain termination events (see F1, F6).
• Ownership after transaction: the filing does not state total post-grant beneficial ownership for these awards.
• Other footnotes: certain holdings are held in family trusts or entities for which the reporting person disclaims beneficial ownership (F2–F4). F5 notes each ADS equals 13 ordinary shares (informational).

Context
These are grant awards (not purchases or sales) and are commonly used for compensation and retention. RSU grants report $0 as the acquisition price at grant; value to the insider will be realized as shares vest (and may be taxable at vesting). The filing appears timely and contains standard vesting and ownership-disclaimer footnotes; it does not indicate any immediate sale or cashless exercise associated with these awards.